查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1418428

血管舒缩症状市场报告：2030 年趋势、预测与竞争分析

Vasomotor Symptoms Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 - page report | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

血管舒缩症状的趋势和预测

预计 2024 年至 2030 年，全球血管舒缩症状市场将以 5.8% 的复合年增长率成长。该市场的主要驱动力是由于久坐的生活方式、遗传、荷尔蒙波动和不良饮食导致血管舒缩症状频率上升，以及资助研发和潜在临床试验的公司。参与企业数量正在增加。全球血管舒缩症状市场的未来充满希望，医院、诊所和专科中心市场充满机会。

血管舒缩症状市场洞察

Lucintel 预测，在预测期内，联合治疗将继续成为有效治疗血管舒缩症状的较大部分。

在这个市场中，在治疗血管舒缩疾病方面拥有丰富专业知识的专科中心将继续占据很大一部分。

由于更年期疾病的高盛行率，在预测期内，北美将继续成为最大的地区。

常问问题

Q1.市场成长预测如何？

A1. 2024年至2030年，全球血管舒缩症状市场预计将以5.8%的复合年增长率成长。

Q2.影响市场成长的主要驱动因素有哪些？

A2. 该市场的主要驱动因素是久坐的生活方式、遗传、荷尔蒙波动和不良饮食导致血管舒缩症状频率增加，以及资助研发和潜在临床试验的公司。参与企业数量正在增加。

Q3.市场的主要细分市场有哪些？

A3. 血管舒缩症状市场的未来看起来充满希望，医院/诊所和专科中心市场存在机会。

Q4.市场上主要企业有哪些？

A4. 治疗血管舒缩症状的主要企业如下。

  • Teva Pharmaceuticals
  • Merck
  • Mithra Pharmaceuticals
  • Procter And Gamble
  • Therapeuticsmd
  • Emcure Pharmaceuticals
  • Eli Lily And Company
  • Novartis
  • Novo Nordisk
  • Pfizer

Q5.未来最大的细分市场是什么？

A5.Lucintel 预计，在有效治疗血管舒缩症状的预测期内，联合治疗仍将占据较大份额。

Q6. 未来五年预计哪个地区的市场最大？

A6. 由于北美地区更年期盛行率较高，因此在预测期内北美将继续成为最大的地区。

Q7. 可以客製化报告吗？

A7. 是的，Lucintel 提供 10% 的客製化服务，无需额外费用。

目录

第一章执行摘要

第二章全球血管舒缩症状市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第三章 2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球血管舒缩症状市场趋势（2018-2023）与预测（2024-2030）
  • 全球血管舒缩症状市场：依治疗方法
    • 雌激素
    • 黄体酮
    • 组合
    • 市售荷尔蒙
    • 抗忧郁症
    • 其他的
  • 全球血管舒缩症状市场：按分销管道
    • 医院药房
    • 零售药房
    • 药局
  • 全球血管舒缩症状市场：依最终用途分类
    • 医院和诊所
    • 专业中心
    • 其他的

第四章 2018-2030年区域市场趋势及预测分析

  • 全球血管舒缩症状市场（按地区）
  • 北美洲血管舒缩症状市场
  • 欧洲血管舒缩症状市场
  • 亚太血管舒缩症状市场
  • 其他地区血管舒缩症状市场

第五章 竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析

第六章 成长机会与策略分析

  • 成长机会分析
    • 全球血管舒缩症状市场的治疗方法成长机会
    • 全球血管舒缩症状市场成长机会（按分销管道）
    • 全球血管舒缩症状市场成长机会（依最终用途）
    • 按地区分類的全球血管舒缩症状市场成长机会
  • 全球血管舒缩症状市场的新趋势
  • 战略分析
    • 新产品开发
    • 全球血管舒缩症状市场容量扩张
    • 全球血管舒缩症状市场的合併、收购与合资企业
    • 认证和许可

第七章主要企业概况

  • Teva Pharmaceuticals
  • Merck
  • Mithra Pharmaceuticals
  • Procter and Gamble
  • TherapeuticsMD
  • Emcure Pharmaceuticals
  • Eli Lily and Company
  • Novartis
  • Novo Nordisk
  • Pfizer
简介目录

Vasomotor Symptoms Trends and Forecast

The future of the global vasomotor symptoms market looks promising with opportunities in the hospitals and clinics and specialty centers markets. The global vasomotor symptoms market is expected to grow with a CAGR of 5.8% from 2024 to 2030. The major drivers for this market are rising frequency of vasomotor symptoms as a result of sedentary lifestyle, heredity, hormonal fluctuations, and poor eating patterns and increase in the quantity of businesses funding R&D and potential clinical trial participants.

A more than 150-page report is developed to help in your business decisions.

Vasomotor Symptoms by Segment

The study includes a forecast for the global vasomotor symptoms by therapy type, distribution channel, end use, and region.

Vasomotor Symptoms Market by Therapy Type [Shipment Analysis by Value from 2018 to 2030]:

  • Estrogen
  • Progesterone
  • Combination
  • OTC Hormone
  • Anti-Depressants
  • Others

Vasomotor Symptoms Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Drug Stores

Vasomotor Symptoms Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals And Clinics
  • Specialty Centers
  • Others

Vasomotor Symptoms Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Vasomotor Symptoms Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies vasomotor symptoms companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the vasomotor symptoms companies profiled in this report include-

  • Teva Pharmaceuticals
  • Merck
  • Mithra Pharmaceuticals
  • Procter And Gamble
  • Therapeuticsmd
  • Emcure Pharmaceuticals
  • Eli Lily And Company
  • Novartis
  • Novo Nordisk
  • Pfizer

Vasomotor Symptoms Market Insights

Lucintel forecasts that combination will remain the larger segment over the forecast period due to effective treatment for vasomotor symptoms.

Within this market, specialty centers will remain the larger segment due to more expertise in treating vasomotor symptoms.

North America will remain the largest region over the forecast period due to high prevalence of menopause in north america.

Features of the Global Vasomotor Symptoms Market

Market Size Estimates: Vasomotor symptoms market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Vasomotor symptoms market size by therapy type, distribution channel, end use, and region in terms of value ($B).

Regional Analysis: Vasomotor symptoms market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different therapy type, distribution channel, end use, and regions for the vasomotor symptoms market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the vasomotor symptoms market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the growth forecast for vasomotor symptoms market?

Answer: The global vasomotor symptoms market is expected to grow with a CAGR of 5.8% from 2024 to 2030.

Q2. What are the major drivers influencing the growth of the vasomotor symptoms market?

Answer: The major drivers for this market are rising frequency of vasomotor symptoms as a result of sedentary lifestyle, heredity, hormonal fluctuations, and poor eating patterns and increase in the quantity of businesses funding R&D and potential clinical trial participants.

Q3. What are the major segments for vasomotor symptoms market?

Answer: The future of the vasomotor symptoms market looks promising with opportunities in the hospitals and clinics and specialty centers markets.

Q4. Who are the key vasomotor symptoms market companies?

Answer: Some of the key vasomotor symptoms companies are as follows.

  • Teva Pharmaceuticals
  • Merck
  • Mithra Pharmaceuticals
  • Procter And Gamble
  • Therapeuticsmd
  • Emcure Pharmaceuticals
  • Eli Lily And Company
  • Novartis
  • Novo Nordisk
  • Pfizer

Q5. Which vasomotor symptoms market segment will be the largest in future?

Answer: Lucintel forecasts that combination will remain the larger segment over the forecast period due to effective treatment for vasomotor symptoms.

Q6. In vasomotor symptoms market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to high prevalence of menopause in north america.

Q7. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the vasomotor symptoms market by therapy type (estrogen, progesterone, combination, OTC hormone, anti-depressants, and others), distribution channel (hospital pharmacy, retail pharmacy, and drug stores), end use (hospitals and clinics, specialty centers, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Vasomotor Symptoms Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Vasomotor Symptoms Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Vasomotor Symptoms Market by Therapy Type
    • 3.3.1: Estrogen
    • 3.3.2: Progesterone
    • 3.3.3: Combination
    • 3.3.4: OTC Hormone
    • 3.3.5: Anti-Depressants
    • 3.3.6: Others
  • 3.4: Global Vasomotor Symptoms Market by Distribution Channel
    • 3.4.1: Hospital Pharmacy
    • 3.4.2: Retail Pharmacy
    • 3.4.3: Drug Stores
  • 3.5: Global Vasomotor Symptoms Market by End Use
    • 3.5.1: Hospitals and Clinics
    • 3.5.2: Specialty Centers
    • 3.5.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Vasomotor Symptoms Market by Region
  • 4.2: North American Vasomotor Symptoms Market
    • 4.2.2: North American Vasomotor Symptoms Market by End Use: Hospitals and Clinics, Specialty Centers, and Others
  • 4.3: European Vasomotor Symptoms Market
    • 4.3.1: European Vasomotor Symptoms Market by Therapy Type: Estrogen, Progesterone, Combination, OTC hormone, Anti-Depressants, and Others
    • 4.3.2: European Vasomotor Symptoms Market by End Use: Hospitals and Clinics, Specialty Centers, and Others
  • 4.4: APAC Vasomotor Symptoms Market
    • 4.4.1: APAC Vasomotor Symptoms Market by Therapy Type: Estrogen, Progesterone, Combination, OTC hormone, Anti-Depressants, and Others
    • 4.4.2: APAC Vasomotor Symptoms Market by End Use: Hospitals and Clinics, Specialty Centers, and Others
  • 4.5: ROW Vasomotor Symptoms Market
    • 4.5.1: ROW Vasomotor Symptoms Market by Therapy Type: Estrogen, Progesterone, Combination, OTC hormone, Anti-Depressants, and Others
    • 4.5.2: ROW Vasomotor Symptoms Market by End Use: Hospitals and Clinics, Specialty Centers, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Vasomotor Symptoms Market by Therapy Type
    • 6.1.2: Growth Opportunities for the Global Vasomotor Symptoms Market by Distribution Channel
    • 6.1.3: Growth Opportunities for the Global Vasomotor Symptoms Market by End Use
    • 6.1.4: Growth Opportunities for the Global Vasomotor Symptoms Market by Region
  • 6.2: Emerging Trends in the Global Vasomotor Symptoms Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Vasomotor Symptoms Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Vasomotor Symptoms Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Teva Pharmaceuticals
  • 7.2: Merck
  • 7.3: Mithra Pharmaceuticals
  • 7.4: Procter and Gamble
  • 7.5: TherapeuticsMD
  • 7.6: Emcure Pharmaceuticals
  • 7.7: Eli Lily and Company
  • 7.8: Novartis
  • 7.9: Novo Nordisk
  • 7.10: Pfizer